Impact Factor
3.29
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.64
555 total citations
h5-index
28
h5 depth signal
Cited share
66.8%
147 of 220
Total citations
555
Citation footprint
Metric signal
2.49
External metric anchor
Self-citation
15.9%
88 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
285
United Kingdom
200
Italy
156
Netherlands
91
Canada
81
Citing Fields of Research
Neurodegenerative Disorders
1,048
Nervous System Disorders
95
Neuromuscular Disorders
80
Postural Control
41
Laryngology
41
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,619
Articles tracked across the journal lifetime
Indexed publication set
220
147 cited publications
Last 12 months
116
9.7 publications/month
Open access share
35.3%
41 OA publications in the last year
Leading citing country
United States
285 citing publications
Leading citing field
Neurodegenerative Disorders
1,048 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v14 n1/2, Mar. 2013-
v14 n1/2, Mar. 2013-
Research Focus & Classification
Indexed Subjects
Neurodegenerative Disorders
Issuing & Sponsoring Bodies
Contributor
World Federation of Neurology. Research Group on Motor Neuron Diseases
Broad Categories
Neurology
Neurodegenerative Disorders
MeSH Descriptors
Amyotrophic Lateral Sclerosis
Frontotemporal Lobar Degeneration
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1080/21678421.2026.2742815
Open DOI
Factors associated with post-tracheostomy survival in Amyotrophic Lateral Sclerosis
02
DOI 10.1080/21678421.2026.2741037
Open DOI
Interventions to support informal carers managing behavioral symptoms in frontotemporal lobar degeneration: a scoping review
03
DOI 10.1080/21678421.2026.2742818
Open DOI
Mapping the evidence on dignity therapy in amyotrophic lateral sclerosis: a scoping review
04
DOI 10.1080/21678421.2026.2745871
Open DOI
Assessing the metabolic rate in patients with Amyotrophic Lateral Sclerosis, Progressive Muscular Atrophy, and Primary Lateral Sclerosis
An increased metabolic rate, or hypermetabolism, is observed in patients with amyotrophic lateral sclerosis (ALS) (1,2). It has been associated with a faster rate of functional decline and increase...
05
DOI 10.1080/21678421.2026.2742816
Open DOI
Specialist psychology provision for ALS/MND: results from a survey of UK ALS/MND services
06
DOI 10.1080/21678421.2026.2738533
Open DOI
Harmonizing ALS research data across multimodal data sets using the OMOP Common Data Model
07
DOI 10.1080/21678421.2026.2742817
Open DOI
N-terminal proVGF modifications related to Amyotrophic Lateral Sclerosis
08
DOI 10.1080/21678421.2026.2743446
Open DOI
Clinical and genetic characterization of FUS -associated ALS in a tertiary cohort
09
DOI 10.1080/21678421.2026.2739760
Open DOI
Assessing consciousness in end-stage ALS: response to young’s commentary
10
DOI 10.1080/21678421.2026.2740377
Open DOI
Correction
Article title: Pridopidine treatment in ALS: subgroup analyses from the HEALEY ALS Platform trialAuthors: Michal Geva, Y. Paul Goldberg, Melanie L. Leitner, Andres Cruz-Herranz, Randal Hand, Kelly ...
Bibliographical & Catalog Notes
Also issued online.